Suzhou, China, Nov. 19, 2019 /Prnewswire/ -- Cstone Pharmaceuticals ("Cstone" Or The "Company", Hkex: 2616) Today Announced That The First Patient Has Been Dosed In The Phase I Bridging Registrational Study Of Ivosidenib (Tibsovo
Found this useful? Share it with your team.
